Logo

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

Share this

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

Shots:

  • The US FDA has approved Keytryda + CT- with/out bevacizumab- for the treatment of patients with persistent- recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test
  • The approval is based on the P-III KEYNOTE-826 trial that demonstrated superior OS and PFS- ORR (68% vs 50%)- mDOR (18.0 vs 10.4mos.)
  • The approval marks the first anti-PD-1 combination approved as a 1L treatment for the targeted patients. Additionally- the FDA converted the accelerated approval of Keytruda as a single agent for recurrent or metastatic cervical cancer to a regular approval based on data from KEYNOTE-826 study

 Ref: Businesswire | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions